Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Aflibercept (EYLEA®)
Aflibercept · 1 trial · 1 indication
To evaluate the long-term safety of ABBV-RGX-314
| Arm | Type | Description |
|---|---|---|
| Standard of Care | OTHER | Dose Level (DL) 1-3 participants who received ABBV-RGX-314 in a parent study will continue to receive standard of care for the study duration. |
| Supplemental Treatment | OTHER | DL4 participants from parent study will be eligible to receive supplement aflibercept through a prespecified timepoint based on protocol-specified criteria if they develop worsening CI-DME or high-risk proliferative diabetic retinopathy (PDR) in the study eye. |
| Name | Type | Description |
|---|---|---|
| Standard of Care | DRUG | Standard of Care |
| Aflibercept | DRUG | Injection |
Inclusion Criteria: * Must provide written, signed informed consent for this study * Must have been enrolled in a previous clinical study of ABBV-RGX-314 for the treatment of DR with or without CI-DME and must have received an SCS injection of ABBV-RGX-314 in that study * Must be willing and able t...
Aflibercept is an investigational small molecule being studied for the treatment of Diabetic Retinopathy (DR). It is currently in Phase 2 clinical development. Aflibercept is also known as EYLEA® and is being developed by AbbVie Inc. (ABBV).
Aflibercept targets and inhibits PGF and VEGFA. These are vascular endothelial growth factors involved in the development of diabetic retinopathy. By inhibiting these targets, Aflibercept aims to address the underlying pathology of the disease.
Aflibercept is being developed by AbbVie Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol ABBV. The drug is in Phase 2 clinical trials for the treatment of Diabetic Retinopathy.
Aflibercept is currently in Phase 2 clinical development for Diabetic Retinopathy. It is an investigational drug and has not yet been approved by regulatory authorities. The ongoing clinical trial is designed to evaluate its safety and efficacy in patients with this condition.
Aflibercept is being studied in a Phase 2 clinical trial with the identifier NCT05296447. This trial is titled "Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy" and is enrolling 100 participants in the United States.
Yes, Aflibercept is also known as EYLEA®. The drug is being developed under the name Aflibercept and is referred to as EYLEA® in some contexts. It is currently in Phase 2 clinical trials for the treatment of Diabetic Retinopathy.